Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to…
HOUSTON, Nov. 4, 2024 /PRNewswire/ -- OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer…
Epic now fully supports version 3 of the United States Core Data for Interoperability standards—over a year ahead of the…
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael WellerAccess the segment here HOUSTON, TX / ACCESSWIRE /…
Garden City, New York--(Newsfile Corp. - November 4, 2024) - Silberstein, Awad & Miklos, P.C. (ASK4SAM), a prominent Bronx-based medical…
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of…
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformationTÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE…
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company…
LOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered…
VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing…